Arterial hypertension treatment with a calcium channel blocker and an ACE inhibitor. Benefits of combination therapy
https://doi.org/10.15829/1560-4071-2013-3-100-103
Abstract
The paper emphases the need for dual antihypertensive therapy and describes its
benefits, such as synergetic hypotensive action and other beneficial effects. One of
the pathogenetically justified variants of combination therapy – a third-generation
dihydropyridine calcium channel antagonist and an angiotensin-converting enzyme
inhibitor – is discussed in more detail.
About the Author
E. O. Taratukhin
N. I. Pirogov Russian National Medical Research University, Moscow, Russia
Russian Federation
Russian Federation
References
1. Ma J., Lee K. – V., Stafford R. S. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension. Hypertension. 2006; 48: 846–52.
2. Katzung B. G. Basic and clinical pharmacology. 10th ed. McGrawHill. 2007; 1179c.
3. Bangalore S., Kamala G., Parker S. et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med, 2007; 120 (8):713–9.
4. Panjabi S., Lacey M., Bancroft T. et al. Treatment adherence, clinical outcomes and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens, 2013; 7 (1):46–60.
5. Silva P. S., Fontana V., Luizon M. R. et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol. 2012; Jun, 17.
6. Cacciatore F., Bruzzese G., Vitale D. F. et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage and oxidative stress in hypertensive patients. Eur J Clin Pharmacol. 2011; 67:877–93.
7. Velez Rueda J. O., Palomeque J., Mattiazzi A. et al. Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensinsystem activity involves CaMKII. J Appl Physiol. 2012; 112:2110–20.
8. Hoque R., Rahman M. S., Iqbal M. et al. Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. Bangl Med Res Counc Bull. 2009; 35:44–8.
9. Mauer M., Zinman B., Gardiner R. et al. Renal and retinal effects of enalapril and losartan in pype 1 diabetes. N Engl J Med. 2009; 361:40–51.
10. Borghi C. Lercanidipine in hypertension. Vasc Health & Risk Manag, 2005; 1: 173–82.
11. Minushkina L. O., Iosava I. K. Lercanidipine in arterial hypertension. Kardiologia, 2012; 52: 70–4. (Русский: Минушкина Л. О., Иосава И. К. Лерканидипин в лечении артериальной гипертензии. Кардиология, 2012; 52:70–4)
12. Yeh J. L., Hsu J. H., Liang J. C. et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharideinterferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis, 2013; 226 (2):364–72.
13. Sakurai-Yamashita Y., Harada N., Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell Mol Neurobiol, 2011; 31:561–7.
14. Borghi C., Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Pt Prefer Adh, 2012; 6:449–55.
15. Cicero A. F., Borghi C. Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipineenalapril. Clin Drug Investig, 2010; 30 (12):843–54.
16. Gupta AK, Arshad S, Poulter NR. Compliance, Safety and Effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension, 2010; 55:399–407.
17. Messerli F. H. Review: fixed-dose drug combinations improve medication compliance compared with free-drug regimens. Evid Based Med, 2008; 13:18–22.
Review
For citations:
Taratukhin E.O. Arterial hypertension treatment with a calcium channel blocker and an ACE inhibitor. Benefits of combination therapy. Russian Journal of Cardiology. 2013;(3):100-103. (In Russ.) https://doi.org/10.15829/1560-4071-2013-3-100-103
Views:
515
Email this article 